- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05342467
Gemeprost Versus Dinoprostone in First Trimester Miscarriages
January 22, 2024 updated by: National University of Malaysia
Gemeprost Versus Dinoprostone in the Medical Management of First Trimester Miscarriages: a Randomized Controlled Study
Comparison between gemeprost and dinoprostone to evacuate first trimester miscarriages.
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
Women who are diagnosed with first trimester missed miscarriages are invited to participate in the study.
They will be randomised to either gemeprost or dinoprostone.
Study Type
Interventional
Enrollment (Estimated)
174
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Rahana Abd Rahman
- Phone Number: +60122719985
- Email: drrahana@ppukm.ukm.edu.my
Study Contact Backup
- Name: Aida Hani Kalok
- Phone Number: +60122024091
- Email: aidahani.mohdkalok@ppukm.ukm.edu.my
Study Locations
-
-
W.Persekutuan
-
Kuala Lumpur, W.Persekutuan, Malaysia, 56000
- Recruiting
- UKM Medical Center
-
Contact:
- Rahana Abd Rahman
- Phone Number: +60122719985
- Email: drrahana@ppukm.ukm.edu.my
-
Kuala Lumpur, W.Persekutuan, Malaysia, 56000
- Recruiting
- UKM Medical Centre
-
Contact:
- Rahana Abd Rahman
- Phone Number: +60122719985
- Email: drrahana@ppukm.ukm.edu.my
-
Contact:
- Aida Hani Kalok
- Phone Number: +60122024091
- Email: aidahani.mohdkalok@ppukm.ukm.edu.my
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- missed miscarriages
- incomplete miscarriages
- first trimester
Exclusion Criteria:
- coagulopathy
- Rhesus negative
- suspected ectopic pregnancy or pregnancy of unknown location
- on anticoagulation drug
- septic miscarriages
- hemodynamically unstable
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Gemeprost
Gemeprost 1 mg inserted 3 hourly for maximum of 5 doses in 24 hours.
|
Intravaginal gemeprost 1 mg inserted 3 hourly for maximum of 5 doses in 24 hours
Intravaginal dinoprostone 3 mg inserted 4 hourly for maximum of 3 doses in 24 hours
|
Active Comparator: Dinoprostone
Dinoprostone 3 mg inserted 4 hourly for maximum of 3 doses in 24 hours.
|
Intravaginal gemeprost 1 mg inserted 3 hourly for maximum of 5 doses in 24 hours
Intravaginal dinoprostone 3 mg inserted 4 hourly for maximum of 3 doses in 24 hours
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of women who achieved complete evacuation
Time Frame: from recruitment until up to one week after commencement of treatment
|
Complete expulsion of product of conception
|
from recruitment until up to one week after commencement of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of women who experienced side effects
Time Frame: from recruitment until up to one week after commencement of treatment
|
side effects towards each drug such as fever, gastrointestinal upset
|
from recruitment until up to one week after commencement of treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Rahana Abd Rahman, National University of Malaysia
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 11, 2021
Primary Completion (Estimated)
November 10, 2025
Study Completion (Estimated)
November 10, 2025
Study Registration Dates
First Submitted
April 17, 2022
First Submitted That Met QC Criteria
April 17, 2022
First Posted (Actual)
April 22, 2022
Study Record Updates
Last Update Posted (Actual)
January 23, 2024
Last Update Submitted That Met QC Criteria
January 22, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pregnancy Complications
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Abortion, Spontaneous
- Abortion, Missed
- Abortion, Incomplete
- Physiological Effects of Drugs
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Oxytocics
- Dinoprostone
- Gemeprost
Other Study ID Numbers
- FF-2021-504
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Medical; Abortion, Fetus
-
Queen Savang Vadhana Memorial Hospital, ThailandRecruitingMedical; Abortion, FetusThailand
-
Gynuity Health ProjectsUnknownMedical; Abortion, FetusBurkina Faso
-
Gynuity Health ProjectsCompletedMedical; Abortion, FetusMoldova, Republic of, United States, Mexico
-
Gynuity Health ProjectsSecretaria de Salud, MexicoCompletedMedical; Abortion, FetusUnited States
-
Gynuity Health ProjectsCompletedMedical Abortion, FetusMoldova, Republic of, Uzbekistan
-
Centre Hospitalier Universitaire de NīmesCompletedMedical; Abortion, FetusFrance
-
Ain Shams Maternity HospitalCompletedMedical; Abortion, FetusEgypt
-
Women's College HospitalCompletedMedical; Abortion, FetusCanada
-
IRCCS Azienda Ospedaliera Universitaria San Martino...CompletedMedical; Abortion, FetusItaly
-
Kanuni Sultan Suleyman Training and Research HospitalCompletedMedical; Abortion, Fetus | Second Trimester AbortionTurkey
Clinical Trials on Gemeprost 1 Mg Vaginal Pessary
-
Meir Medical CenterUnknownCystocele | Uterine Prolapse | Rectocele | Use of Pessary Reduce the Number of Prolapse Recurrence
-
Liv Labs Inc.Eunice Kennedy Shriver National Institute of Child Health and Human Development...Recruiting
-
Servicio de Salud Metropolitano Sur OrientePontificia Universidad Catolica de ChileUnknownQuality of Life | Pelvic Organ ProlapseChile
-
ConTIPI MedicalUnknown
-
Reia, LLCCompleted
-
University Hospital, GhentRecruiting
-
Assuta Hospital SystemsCompletedStress Urinary IncontinenceIsrael
-
Chinese University of Hong KongKwong Wah HospitalRecruitingPelvic Organ ProlapseHong Kong
-
Procter and GambleCompletedStress Urinary IncontinenceUnited States
-
Aziende Chimiche Riunite Angelini Francesco S.p.ACross Research S.A.CompletedHealthy WomenSwitzerland